新辅助化疗联合肿瘤细胞减灭术后热灌注化疗治疗晚期卵巢癌疗效观察

目的探讨新辅助化疗联合肿瘤细胞减灭术后热灌注治疗晚期卵巢癌的临床疗效。方法选取2009年4月至2012年7月间收治的60例晚期卵巢癌患者,按收治时间顺序分为两组,观察组患者术前采取新辅助化疗,术后联合腹腔内热灌注辅助化疗1次(顺铂80mg),术后给予TC/TP方案化疗;对照组患者采取常规肿瘤细胞减灭术+术后TC/TP方案化疗,比较两组患者在手术时间、出血量、腹水量、术后化疗疗程、疗效、复发与死亡、生存率等方面的差异。结果观察组患者手术时间为(215.34±32.76)min,腹水量为(678.35±32.32)ml,失血量为(502.89±118.53)ml,对照组患者手术时间为(275.35±42.98)min,腹水量为(1242.24±204.3)ml,失血量为(759.64±153.45)ml,两组比较差异有统计学意义(P<0.05)。观察组患者术后化疗疗程较对照组明显减少(P<0.05)。观察组患者总有效率为83.3%,对照组为33.3%,两组比较差异有统计学意义(P<0.05)。观察组和对照组患者1年生存率比较,差异有统计学意义(P<0.05)。结论晚期卵巢癌患者采取术前新辅助化疗联合肿瘤细胞减灭术、术后热灌注辅助化疗,对患者预后和疗效较常规的方法有较大提高,值得在临床上进行推广。

Observation of curative effect of hyperthermic perfusion chemotherapy in treatment of advanced o- varian carcinoma cytoreductive surgery after neoadjuvant chemotherapy combined with tumor cells

Objective To explore the new adjuvant chemotherapy combined with tumor ceils de- creased clinical death postoperative hyperthermic perfusion in the treatment of advanced ovarian cancer. Methods According to our hospital from 60 cases of advanced ovarian cancer from 2009 April to 2012 July were patients, divided into two groups according to the treated time sequence, the observation group patients before taking new adjuvant chemotherapy combined with intraperitoneal hyperthermic perfusion chemotherapy （cisplatin 1 80mg） treatment, given TC/TP chemotherapy after surgery, the control group adopted conven- tional tumor cells cytoreductive surgery and postoperative chemotherapy of TC/TP regimen for treatment, compared two groups of patients in operation time, bleeding volume, volume of ascites, postoperative chem- otherapy, curative effect, recurrence and death, survival data difference. Results In observation group, the operation time was （215.34 ±32. 76） min, the volume of ascites was （678. 35 ±32. 32） ml, blood loss volume was（502. 89 ± 118. 53）ml, In control group, the operation time was （275.35 ±42. 98）min, the volume of ascites was （ 1242. 24 ±204. 3 ）ml, blood loss volume was （759. 64 ± 153.45 ）ml, the differ- ence was statistical significance （ P 〈 0. 05 ）. The courses of postoperative chemotherapy in observation group was decreased significantly than in the control group （ P 〈 0. 05 ）. The overall efficiency of observation group was 83.3%, compared with the control groups 33.3% , the difference was statistical significance （ P 〈 O. 05）. The difference of 1 year survival rate has statistical significance （P 〈 O. 05 ）. Conclusion In clinical practice for patients with advanced ovarian cancer by neoadjuvant chemotherapy and cytoreductive surgery postoperative hyperthermic perfusion chemotherapy, has greatly improved the prognosis of patients and compared with conventional, worthy of clinical popularization.